Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Vosevi on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
USA
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Vosevi (sofosbuvir/velpatasvir/voxilaprevir) is a fixed-dose combination antiviral approved by the FDA for the treatment of adult patients with chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis, across genotypes 1 through 6, who have previously been treated with an NS5A inhibitor-containing regimen, or genotype 1a or 3 patients previously treated with sofosbuvir without an NS5A inhibitor.
Vosevi combines three direct-acting antivirals that target different steps of the HCV lifecycle: sofosbuvir inhibits the NS5B polymerase, velpatasvir inhibits NS5A, and voxilaprevir inhibits the NS3/4A protease. Together, this triple combination is designed to be effective even in patients who did not achieve cure with prior NS5A-inhibitor-based therapy.
Vosevi is intended for treatment-experienced HCV patients who did not achieve sustained virologic response with a prior regimen, offering a retreatment option across a broad range of genotypes.
The recommended dose of Vosevi is one tablet taken orally once daily with food, for a treatment duration of 12 weeks.
Boxed Warning — Vosevi: Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with Vosevi. HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct-acting antivirals and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation during and after treatment.
Cases of hepatic decompensation and hepatic failure, including fatal cases, have been reported in patients treated with HCV direct-acting antivirals, mostly in patients with cirrhosis.
Serious symptomatic bradycardia has been reported when Vosevi is coadministered with amiodarone. Coadministration is not recommended, and alternative antiviral therapy should be considered if amiodarone use cannot be avoided.
Coadministration with P-glycoprotein inducers or moderate to strong CYP2B6, CYP2C8, or CYP3A4 inducers is not recommended, as this may significantly reduce Vosevi's effectiveness.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Vosevi is manufactured and marketed by Gilead Sciences. It is sourced through authorized distribution channels for patients seeking named-patient import into India.
Patients typically need a valid prescription from a treating hepatologist or infectious disease specialist confirming HCV diagnosis, genotype, and prior treatment history. NPP's regulatory team assists in preparing and verifying the documentation needed for a compliant import.
As an FDA-approved therapy for treatment-experienced chronic HCV infection, Vosevi is sourced through authorized channels and imported under GDP-compliant logistics to preserve product quality throughout transit.
NPP sources Vosevi directly from authorized pharmaceutical distributors to ensure product authenticity and full traceability. Every shipment is handled under Good Distribution Practice (GDP) conditions from origin to the patient's doorstep.
Vosevi should be stored below 30°C, and this condition is maintained throughout transit.
Once documentation and regulatory approvals are in place, delivery timelines are communicated transparently at the time of quotation, accounting for import clearance and last-mile logistics to the patient's city.
Patients across India can access Vosevi through NPP's regulated import pathway, with hepatology specialists in major cities supporting the treatment process.
Leading hospitals in Mumbai support hepatology care coordination and documentation for Vosevi access.
Delhi's major hospitals assist patients with prescription support and documentation for Vosevi.
Bangalore's specialist network offers access coordination for eligible HCV patients seeking Vosevi.
Chennai-based hepatology specialists coordinate Vosevi access alongside comprehensive hepatitis C care.
Hyderabad's care institutions support patients pursuing Vosevi therapy.
Kolkata's specialist centers help coordinate documentation and treatment access for Vosevi.
Pune-based specialists assist with prescription support and Vosevi treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Vosevi.
Kochi's specialist units assist patients with the documentation needed for Vosevi access.
Chandigarh's care centers support Vosevi treatment coordination for patients from North India.
Jaipur's specialists help patients navigate the Vosevi access process.
Lucknow-based centers assist patients pursuing Vosevi therapy.
Bhubaneswar's institutions support access to Vosevi for eligible patients.
Guwahati's specialists help coordinate Vosevi access for patients across the Northeast.
Patients in other cities across India can also access Vosevi through NPP's nationwide coordination network.
Last Updated: 15 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
